Over the past decade, a diverse group of new disease-modifying therapies (DMTs) for multiple sclerosis (MS) treatment has entered the market.
1,2 These treatments have different modes of action, but all modulate and interfere with the patient’s immune response, thereby raising concerns about adverse effects, such as an increased susceptibility to infections.